FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549
------------------------

Check this box if no longer subject	STATEMENT (
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursi

## OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     HO WILLIAM						2. Issuer Name and Ticker or Trading Symbol RAPT Therapeutics, Inc. [ RAPT ]										p of Reporti plicable) ctor er (give title	Ü	10% Ov	vner	
(Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 08/30/2022										X belo	w) Chief Med	dical	below) Officer			
(Street) SOUTH FRANCE	isco C	CA 94080					4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	f, or	Ben	efici	ally Owr	ned				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day				Execution		cution I	Oate,	Transaction Disposed Code (Instr. 5)		es Acquired (A Of (D) (Instr. 3,			nd Secur Benef	icially d Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
										v	Amount	(A) (D)	) or )	Price	Trans	action(s) 3 and 4)			(Instr. 4)	
Common Stock 08/30/2					2022				S <sup>(1)</sup>		2,500	]	D	\$28.	13 5	3,035		D		
		Ta	ble II -								osed of, convertib					d				
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			ion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership et (Instr. 4)	
					Code	\v	(A) (D)		Date Exercisable		Expiration Date	of Title Shar								

## **Explanation of Responses:**

 $1. \ The \ sales \ reported \ in \ this \ Form \ 4 \ were \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ Reporting \ Person.$ 

## Remarks:

/s/ Rodney Young, Attorneyin-Fact for William Ho

08/31/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.